心血管光学相干断层扫描（OCT）成像市场（2026—2031）
Mordor 预计，心血管光学相干断层扫描（OCT）成像市场规模将由2026年的12.3亿美元增至2031年的18.7亿美元，期间复合年增长率为8.78%。2025年血管内 OCT 成像系统占58.66%，北美占39.44%并为最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
Mordor 预计，心血管光学相干断层扫描（OCT）成像市场规模将由2026年的12.3亿美元增至2031年的18.7亿美元，期间复合年增长率为8.78%。2025年血管内 OCT 成像系统占58.66%，北美占39.44%并为最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 8.78% | 机构预测 |
| 市场规模 | 2026 | USD 1.23 billion | 机构预测 |
| 市场规模 | 2031 | USD 1.87 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| application | acute coronary syndrome and MINOCA assessment | 2025 | 55.660% |
| end_user | hospitals and tertiary care centers | 2025 | 53.560% |
| geography | North America | 2025 | 39.440% |
| product_type | intravascular OCT imaging systems | 2025 | 58.660% |
| technology_and_imaging_architecture | frequency-domain OCT and Fourier-domain OCT | 2025 | 47.760% |
关键结论
- application 维度中，acute coronary syndrome and MINOCA assessment 在 2025 年的公开份额为 55.66%。
- end_user 维度中，hospitals and tertiary care centers 在 2025 年的公开份额为 53.56%。
- geography 维度中，North America 在 2025 年的公开份额为 39.44%。
- product_type 维度中，intravascular OCT imaging systems 在 2025 年的公开份额为 58.66%。
- technology_and_imaging_architecture 维度中，frequency-domain OCT and Fourier-domain OCT 在 2025 年的公开份额为 47.76%。
主要参与者
- Abbott Laboratories
- Boston Scientific Corporation
- Leica Microsystems GmbH
- Koninklijke Philips N.V.
- Carl Zeiss Meditec AG
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Increasing use of intravascular imaging in complex PCI | +2.100% | Global, strongest in North America and Western Europe where guideline compliance monitoring is active | Short term (≤ 2 years) |
| AI-assisted stent sizing and optimization | +1.800% | North America and the EU as early adopters, followed by Japan and South Korea | Medium term (2-4 years) |
| Rising cardiovascular disease and complex lesion burden | +1.400% | Global, with high relevance in China, India, and the Middle East and Africa | Long term (≥ 4 years) |
| Saline-compatible and low-contrast OCT workflows | +0.900% | Global, with greater relevance for populations with high chronic kidney disease prevalence | Medium term (2-4 years) |
| Cath-lab integration, co-registration, and automated reporting | +0.700% | North America, Western Europe, and Japan | Medium term (2-4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Contrast use and renal-risk concerns in conventional OCT workflows | -0.900% | Global, with greater relevance in South Asia, the Middle East and Africa, and aging populations with high chronic kidney disease prevalence | Medium term (2-4 years) |
| Procedure-time, radiation, and operator-training burden | -0.700% | Emerging markets and lower-volume community hospitals globally | Medium term (2-4 years) |
| Evidence, reimbursement, and governance variability | -0.600% | Asia-Pacific excluding Japan and South Korea, the Middle East and Africa, and South America | Long term (≥ 4 years) |
报告关注的关键问题
What is the 2026 value of the cardiovascular OCT imaging market?
The cardiovascular OCT imaging market was valued at USD 1.23 billion in 2026 and is projected to reach USD 1.87 billion by 2031, at an 8.78% CAGR.
What is driving adoption of cardiovascular OCT imaging?
Stronger support for imaging-guided PCI in complex lesions, AI-assisted stent planning, and low-contrast workflows are supporting adoption.
Which product category is growing fastest in cardiovascular OCT imaging?
OCT imaging catheters are projected to grow at a 10.12% CAGR through 2031, supported by recurring use in PCI procedures.
Which application has the highest growth forecast?
Stent optimization has the highest forecast growth among applications, at an 11.45% CAGR through 2031.
Which region is expected to grow fastest?
Asia-Pacific is expected to grow at an 11.88% CAGR through 2031, supported by reimbursement in Japan and expanding catheterization capacity in key countries.
Why do low-contrast OCT workflows matter for PCI?
They can reduce concerns over iodinated contrast exposure in patients with chronic kidney disease and may support broader use of imaging-guided PCI.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence